Take a look at our previous reports:

Pioneering science
to transform patient outcomes


Annual Report 2024

scroll for more

Letter from
the Chair and CEO

At Galapagos, our focus is clear: developing innovative therapies to improve patient outcomes. This past year has been instrumental in our journey to transform cell therapy.

Dr. Paul Stoffels, Chair and Chief Executive Officer

Financial Highlights

Group Net Revenues
313.2
million
Read more
Cash Position
3,317.8
million
Read more
Deferred Income
1,071.4
million
Read more
R&D Expenditure
343.6
million
Read more

Highlights

Sustainability Statements

Key Achievements